
HeartBeam (BEAT) Stock Forecast & Price Target
HeartBeam (BEAT) Analyst Ratings
Bulls say
HeartBeam is a medical technology company with a strong financial position and innovative patented technology platform. The company just initiated a pilot study for its extended-wear ECG patch that can detect ischemia outside of traditional medical settings, has a cash position of $12.4M after a successful public offering, and plans to expand into heart attack detection. This strategic focus on decentralized cardiovascular diagnostics, efficient practice-level sales, and potential commercialization through concierge medicine gives HeartBeam a positive outlook for the future, making it a strong buy with a bright future ahead.
Bears say
HeartBeam is facing several risks that could impact its potential for commercial success, including potential failures in clinical trials for additional indications, challenges in achieving commercial success due to market size, and dilution risk. The company also reported a net loss of $4.7 million in 1Q26 and does not expect meaningful revenue until 2H26. There is also the risk of slower sales ramp-up and the reliance on a patient-pay model for early commercialization, potentially hindering broader adoption. While HeartBeam has a strong intellectual property portfolio and has signed commercial partnerships with prestigious medical practices, competition from larger companies in the remote cardiac monitoring space may pose a threat to its market positioning. Overall, the current estimated market value of $168 million and projected revenue of $500-$1,000 per patient do not seem to justify the risks involved, leading to a negative outlook on HeartBeam's stock.
This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares